Please assess the completion status of the following clinical trial:

Trial Title: Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Willing to provide informed consent~* ECOG performance status 0-2~* Histologically confirmed non-small cell lung carcinoma~* Locally advanced Stage IIIA or IIIB lung carcinoma according to AJCC 7th edition~* History of at least 10-pack-years of smoking~* Not undergoing surgical resection~* Assessment by medical oncologist and radiation oncologist, with adequate bone marrow, hepatic and renal function for administration of platinum-based chemotherapy~Exclusion Criteria:~* Contraindications to MRI~* Serious medical comorbidities (such as unstable angina, sepsis) or other contraindications to radiotherapy or chemotherapy~* Prior history of lung cancer within 5 years~* Prior thoracic radiation at any time~* Metastatic disease. Patients who present with oligometastatic disease where all metastases have been ablated (with surgery or radiotherapy) are candidates if they are receiving chemoradiotherapy to the thoracic disease with curative intent.~* Inability to attend full course of radiotherapy or follow-up visits~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Arm (Type: ACTIVE_COMPARATOR): Standard platinum-based chemoradiotherapy, total radiation dose 60 Gy in 30 fractions
- Experimental Arm (Type: EXPERIMENTAL): Functional-lung avoidance radiotherapy, total dose 60 Gy in 30 fractions, with concurrent platinum-based chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).